Determination of Regulatory Review Period for Purposes of Patent Extension; GILOTRIF

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for the patent extension of GILOTRIF, a human drug product, following a submission to the U.S. Patent and Trademark Office (USPTO). The FDA is publishing this notice as required by law.